Abstract:OBJECTIVE:To investigate the expressions of glypican-3 (GPC3) mRNA in hepatocellular carcinoma (HCC) tissues and peripheral blood cells (PBCs), and to determine the values of GPC3 mRNA in the diagnosis of HCC and HCC micrometastasis.METHODS:Using semi-quantitative and nested reverse transcription polymerase chain reactions (RT-PCR), we detected the expressions of AFP and GPC3 genes in the tissues of 41 HCC, 41 paracancer and 52 non-HCC liver samples (41 far from HCC tissues and 11 normal liver tissues), and in the PBCs of 67 specimens from subjects.RESULTS:The semi-quantitative RT-PCR displayed GPC3 mRNA was expressed in all samples of tissues and PBCs, and the relative intensities of its expressions in HCC, paracancer, non-HCC liver tissues were 78.9 +/- 35.5, 30.6 +/- 21.6, 23.8 +/- 15.5 respectively. The AFP mRNA expression values were 61.2 +/- 32.6, 31.5 +/- 23.6, and 21.2 +/- 15.9 respectively. The expression of each gene in HCC differed significantly from those in other two kinds of tissue samples (P < 0.01). The expressions of GPC3 mRNA and AFP mRNA, accounting for 80.5% and 63.4% in all the HCC tissues, were higher than their respective peak values in the tissues of non-HCC liver (+1.96s), but the expressions of at least one of the two genes was elevated in 92.7% of all the HCC tissues. There was a significant difference between combined detection of two genes and single AFP mRNA detection in HCC tissues (P < 0.01). Clinicopathologically, AFP mRNA was related with the grade of HCC and serum AFP, while GPC3 mRNA was related with not only the grade of HCC but also the invasion of HCC. The relative intensities of GPC3 mRNA expressions in PBCs of 67 specimens was 15.9 +/- 9.0, and GPC3 mRNA expressed in three kinds of tissue samples were all stronger than its counterparts in PBCs (P < 0.01). The GPC3 mRNA expression values in PBCs of the HCC group and the non-HCC group were respectively 16.1 +/- 8.3, 15.6 +/- 10.2, there was no significant difference between the two groups. Of the HCC metastasis group and the HCC non-metastasis group, the respective GPC3 mRNA expression values in PBCs were 16.0 +/- 9.0 and 16.3 +/- 7.7, there was also no significant difference between the two groups. The nested RT-PCR showed that the positive rates of AFP mRNA expressions in PBCs from the HCC group and the non-HCC group were 56.1% and 23.1%, and the difference between the two groups was significant (P = 0.011). The positive rates of AFP mRNA expressions in PBCs from the HCC metastasis group and the HCC non-metastasis group were 80.9% and 30.0%, and there was also a significant difference between the two groups (P = 0.002).CONCLUSIONS:Although GPC3 mRNA is expressed broadly, it still may serve as a potential tissue biomarker in the diagnosis of HCC. Detecting the expression of the two genes in the tissues will improve the screening and diagnosis of HCC. GPC3 is prevalently transcribed in the PBCs, but we have not found any relationship between the GPC3 expression in PBCs and the metastasis or recurrence of hepatocellular carcinoma, thus we can not identify HCC micrometastasis with GPC3 mRNA.

Expression of Glypican 3 Enriches Hepatocellular Carcinoma Development-Related Genes and Associates with Carcinogenesis in Cirrhotic Livers

Diagnostic Value of Glypican-3, Arginase-1 and Hepatocyte Paraffin Antigen -1 in Differentiating Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma

Glypican‐3: A Promising Biomarker for Hepatocellular Carcinoma Diagnosis and Treatment

Expression of glypican-3 in hepatocellular carcinoma and its clinical significance

Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.

Elevated GPC3 level promotes cell proliferation in liver cancer.

Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: A tissue microarray-based study

Significance of Glypican-3 Mrna Expression in Hepatocellular Carcinoma Tissues and Peripheral Blood Cells

GPC-3 in Hepatocellular Carcinoma: Current Perspectives

Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study

Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients

Dysplastic Nodules with Glypican-3 Positive Immunostaining: a Risk for Early Hepatocellular Carcinoma.

Upregulation of Glypican-3 Expression in Hepatocellular Carcinoma but Downregulation in Cholangiocarcinoma Indicates Its Differential Diagnosis Value in Primary Liver Cancers.

Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.

The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression

Diagnostic Utility of Glypican-3 for Hepatocellular Carcinoma on Liver Needle Biopsy.

Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma

Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis

[Significance of Glypican-3 Immunohistochemistry in Diagnosis of Hepatocellular Carcinoma].

Glypican-3 Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells Through Erk Signaling Pathway

Long noncoding RNA GPC3-AS1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.